About Acidic leucine-rich nuclear phosphoprotein 32 family member E
Acidic leucine-rich nuclear phosphoprotein 32 family member E (ANP32E) is a protein
from Homo sapiens identified by UniProt accession
Q9BTT0, 268 residues long.
MolForge cross-references it against 0 known binders and
53 disease associations.
Target properties
| Protein name | Acidic leucine-rich nuclear phosphoprotein 32 family member E |
|---|
| UniProt accession | Q9BTT0 |
|---|
| Gene | ANP32E |
|---|
| Organism | Homo sapiens |
|---|
| Length | 268 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (53)
Diseases linked to this target (Open Targets).
- vital capacity · score 0.32
- lymphocyte percentage of leukocytes · score 0.25
- bone mineral content measurement · score 0.23
- chronotype measurement · score 0.22
- testosterone measurement · score 0.22
- body height · score 0.19
- forced expiratory volume · score 0.15
- granulocyte count · score 0.15
- neutrophil count · score 0.15
- appendicular lean mass · score 0.12
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q9BTT0-F1 | alphafold | PREDICTED | 76.44 | — |
Amino-acid sequence (268 residues)
MEMKKKINLE LRNRSPEEVT ELVLDNCLCV NGEIEGLNDT FKELEFLSMA NVELSSLARL PSLNKLRKLE LSDNIISGGL EVLAEKCPNL TYLNLSGNKI KDLSTVEALQ NLKNLKSLDL FNCEITNLED YRESIFELLQ QITYLDGFDQ EDNEAPDSEE EDDEDGDEDD EEEEENEAGP PEGYEEEEEE EEEEDEDEDE DEDEAGSELG EGEEEVGLSY LMKEEIQDEE DDDDYVEEGE EEEEEEEGGL RGEKRKRDAE DDGEEEDD
Explore Acidic leucine-rich nuclear phosphoprotein 32 family member E with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets